Searching for the sales holy grail
Consolidators that want to achieve growth through additional sales may have embarked on a long and ultimately unfruitful quest, Tony Cornell says
Consolidators faced with difficulties in securing funding have had to come up with alternative growth strategies to satisfy investors and keep staff motivated. Collectively, their solution is to go for organic growth through additional sales. In effect they are searching for the holy grail that has eluded most of the sector for many years. The challenges are enormous and most will find it hard to make up for lost business, let alone achieve organic growth through sales. Growth from increased
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact info@insuranceage.co.uk.
You are currently unable to print this content. Please contact info@insuranceage.co.uk to find out more.
You are currently unable to copy this content. Please contact info@insuranceage.co.uk to find out more.
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email info@insuranceage.co.uk
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email info@insuranceage.co.uk
Most read
- In Depth: Managing cyber risk in an ever-changing security landscape
- RSA confirms trading structure ahead of NIG integration
- In Depth: Cyber risk and AI – friend or foe?